The European Federation of Pharmaceutical Industries and Associations (EFPIA) released new research that evaluates the effects of the European Commission's draft Pharmaceutical Legislation on Europe's competitiveness, the future of its life science sector, and patient care.

The research shows that the Commission's plans would make Europe less innovative than the U.S., China, and Japan.

The numbers reveal that the Commission's ideas to cut down on data protection, which is crucial for protecting new medicines, will decrease the motivation for companies to invest in these medicines by 55% in Europe over the next 15 years.

A major pharmaceutical rules overhaul, proposed by the European Commission in April, could see Europe's share in global research and development ...

Full story available on